ChemoMetec Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Martin Behrens

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Martin Behrens

less than a year

Permanencia

Mr. Martin Helbo Behrens serves as CEO at ChemoMetec A/S since March 13, 2024. He is Chief Operating Officer of ChemoMetec A/S from December 2023. He was Vice Chief Operating Officer of ChemoMetec A/S from...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Hans Glensbjerg	Senior Advisor	less than a year	kr.20.00k	3.62% DKK 197.3m
Martin Behrens	CEO & COO	less than a year	sin datos	sin datos
Niels Nielsen	Chief Financial Officer	1.5yrs	sin datos	sin datos
Christopher Runchel	Chief Sales Officer	no data	sin datos	sin datos
Marta Planaguma	Chief Marketing & Strategy Officer	less than a year	sin datos	sin datos
Lisbet Helles	Head of Marketing	less than a year	sin datos	sin datos
Søren Kjærulff	Head of R&D	no data	sin datos	sin datos
Kenneth Paustian	Head of Finance	1.3yrs	sin datos	sin datos
Bo Nielsen	Chief R&D Officer and Physicist & Project Manager	less than a year	sin datos	sin datos

0.4yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 0DZ0 no se considera experimentado ( 0.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Peter Reich	Independent Director	9.6yrs	kr.40.00k	sin datos
Kristine Faerch	Independent Director	3.6yrs	sin datos	0.00032% DKK 17.4k
Niels Thestrup	Chairman	2.6yrs	sin datos	0.0030% DKK 163.3k
Betina Hagerup	Independent Director	2.6yrs	sin datos	0.0017% DKK 91.5k

3.1yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de 0DZ0 se considera experimentada (3 años de antigüedad promedio).

ChemoMetec Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

ChemoMetec A/S Announces CEO Changes

ChemoMetec A/S Announces Executive Changes

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

ChemoMetec A/S, Annual General Meeting, Oct 12, 2023

Less than half of directors are independent

Recent updates

New major risk - Share price stability

Now 24% overvalued

Investor sentiment deteriorates as stock falls 17%

ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24

New major risk - Share price stability

ChemoMetec A/S Announces CEO Changes

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 32%

First half 2024 earnings released: EPS: kr.4.05 (vs kr.6.06 in 1H 2023)

ChemoMetec A/S Maintains Earnings Guidance for the Year 2024

ChemoMetec A/S Announces Executive Changes

Investor sentiment improves as stock rises 29%

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Upcoming dividend of kr.6.00 per share at 1.8% yield

Chemometec A/S Proposes Dividend for the 2022/23 Financial Year

Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022)

New minor risk - Financial data availability

ChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024

ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023

Investor sentiment improves as stock rises 16%

First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022)

Investor sentiment deteriorates as stock falls 17%

ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023

Investor sentiment deteriorated over the past week

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021)

ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023

ChemoMetec A/S, Annual General Meeting, Oct 12, 2023

Less than half of directors are independent

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of kr.4.00 per share

Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020)

First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020)

New 90-day high: kr.585

New 90-day high: kr.529

New 90-day high: kr.458

Full year earnings released - EPS kr.3.51

New 90-day high: kr.403

New 90-day high - kr.401

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad